Les TurskiLes Turski MD PhD, Chief Executive Officer

Professor of Pharmacology, Georg-August-University Göttingen, Germany

Dr. Turski is a physician serving the Wisconsin Technology Innovation Initiative at the University of Wisconsin-Madison as the Chief Executive Officer and the German Center for Neurodegenerative Disorders in Bonn as Professor of Pharmacology.

Turski trained in internal medicine and obtained his MD from the Feliks-Skubiszewski-Medical University in Lublin and his PhD from the Georg-August-University in Göttingen. He received his management education from the University of Michigan Business School in Ann Arbor and from the London Business School. He holds Polish and German medical licenses and is board certified in clinical pharmacology, and in pharmacology and toxicology.

Turski started his professional career at the Medical University in Lublin in 1978 and continued since 1981 in Göttingen at the Max-Planck-Institute for Experimental Medicine. Since 1987 he worked for Schering in Berlin as the Head of Experimental Neurology and then since 1997 for Eisai at the University College London as the Head of Pharmacology.

In the years 1999 to 2012 he served the Solvay Pharmaceuticals in Weesp, Hannover, and Dijon as the Global Head of Research.

Since 1993 he has taught pharmacology and toxicology at the University of Göttingen.

Turski has published 182 articles in peer-reviewed journals and 40 book chapters. He has delivered 102 invited lectures and edited 15 books.

His work is relevant for understanding and therapy of neurological and psychiatric disorders, cardiometabolic disorders, and of cancer.


Richard MossRichard L. Moss, PhD

Chief Scientific Officer

Richard L. Moss received his PhD from the University of Vermont. He followed with postdoctoral studies at the Boston Biomedical Research Institute before joining the faculty at the University of Wisconsin-Madison in 1979.

Moss was chair of the Department of Physiology from 1988 until becoming a senior associate dean at the University of Wisconsin School of Medicine and Public Health in 2009.

He also is the founder and director of the UW-Madison Cardiovascular Research Center, and co-founder and executive director of the Master of Science in Biotechnology Program.

Heart and skeletal muscle physiology is Moss’ primary research interest. His laboratory studies contractile processes in heart and skeletal muscles and alterations in contraction in diseases such as heart failure. A primary focus of his research is the set of mechanisms by which calcium, various physical factors and signal transduction pathways regulate myocardial contraction.

In 2007, he was recognized for his research contributions with an honorary MD degree from Uppsala University in Sweden. He has been a member of numerous NIH study sections and other peer-review committees, editor for 11 scientific journals and a guest lecturer or invited speaker across America, Europe and Japan.

Moss has served in many national leadership positions, including as president of the International Society for Heart Research and on the executive council of the Biophysical Society.


Kurt ZimmermanKurt J. Zimmerman, M.S.

Chief Financial Officer

Kurt J. Zimmerman is Director of the Master of Science in Biotechnology Program at the University of Wisconsin-Madison. Zimmerman teams with faculty on course development and delivery, collaborates actively with the biotechnology industry on related projects, and works with M.S. in Biotechnology students on career and academic issues.

Prior to joining the M.S. in Biotechnology, Zimmerman worked in the nationally ranked manufacturing and online programs in the College of Engineering at UW-Madison, and spent 5 years in a variety of roles within the UW System, including fundraising, corporate relations, government lobbying and human resources. Zimmerman began his career in Stamford, Connecticut as a fundraiser and government lobbyist.

Zimmerman is a frequent speaker on topics relating to career transitions, career management and professional communication. He is also a consultant to Fortune 500 companies on issues relating to continuing education at the graduate level.